Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spurred By Necessity, Industry And Academia Are Learning To Share

Executive Summary

After a prior era of failed collaborations, industry and academia are increasingly joining forces in ways that better accommodate each others’ capabilities and goals – and, they hope, will create more value and ultimately greater improvements to human health.

You may also be interested in...



Check Again: The Problem With Reproducibility

Promising academic results prove elusive when the experiments are run again, threatening reputations and wasting industry resources. Everyone is scrambling for a fix, but is the problem as bad as it seems, and do we really need a top-down solution?

Pfizer, Alliance For Lupus Research To Co-Fund Translational Projects

Pfizer’s partnership with the Alliance for Lupus Research to co-fund translational projects within the context of the pharma’s CTI program is a first. It’s a novel way to speed promising science into the clinic. But can Pfizer, a non-profit research foundation, and academic researchers reconcile their new roles and variant cultures to make the model work?

Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So

SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt

Related Content

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel